Keybanc Maintains Overweight on Recursion Pharmaceuticals, Raises Price Target to $15
Portfolio Pulse from richadhand@benzinga.com
Keybanc analyst Scott Schoenhaus maintains an Overweight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and raises the price target from $12 to $15.
July 13, 2023 | 8:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Recursion Pharmaceuticals' price target has been raised from $12 to $15 by Keybanc, maintaining an Overweight rating.
The news of Keybanc maintaining an Overweight rating and raising the price target for Recursion Pharmaceuticals is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100